Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice

Cheng, David; Low, Jac Kee; Logge, Warren; Garner, Brett; Karl, Tim

doi:10.1007/s00213-014-3478-5

Cited by 144 publications

(141 citation statements)

References 70 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Though this effect is most often attributed to the psychoactive properties of THC, to some it seems counterintuitive to treat a progressive cognitive disorder with the derivatives of a drug known to worsen cognitive impairment. On the other hand, CBD was recently shown to improve socialization and object recognition in transgenic AD mice [94]. This reinforces the concept that the therapeutic effects of cannabinoids, particularly those without significant psychoactive effects, should continue to be examined.…”

Section: Sleep Disorderssupporting

confidence: 53%

Medical marijuana in neurology

Benbadis

Sanchez‐Ramos

Bozorg

et al. 2014

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinical studies. A small number of high-quality clinical trials support the safety and efficacy of cannabinoids for treatment of spasticity of multiple sclerosis, pain refractory to opioids, glaucoma, nausea and vomiting. Lower level clinical evidence indicates that cannabinoids may be useful for dystonia, tics, tremors, epilepsy, migraine and weight loss. Data are also limited in regards to adverse events and safety. Common nonspecific adverse events are similar to those of other CNS 'depressants' and include weakness, mood changes and dizziness. Cannabinoids can have cardiovascular adverse events and, when smoked chronically, may affect pulmonary function. Fatalities are rare even with recreational use. There is a concern about psychological dependence, but physical dependence is less well documented. Cannabis preparations may presently offer an option for compassionate use in severe neurologic diseases, but at this point, only when standard-of-care therapy is ineffective. As more high-quality clinical data are gathered, the therapeutic application of cannabinoids will likely expand.

show abstract

Section: Sleep Disorderssupporting

confidence: 53%

Medical marijuana in neurology

Benbadis

Sanchez‐Ramos

Bozorg

et al. 2014

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…The meaning of this finding is still unknown. Imipramine and CBD presented protective effects under of different animal models of neurodegenerative conditions, such as brain ischemia (Pazos et al, 2012;Schiavon et al, 2010;Schiavon et al, 2014), Alzheimer's disease (Cheng et al, 2014), Parkinson's disease (LastresBecker et al, 2005), and schizophrenia (Gomes et al, 2015). The proneurogenic activity of CBD observed in the SVZ, therefore, might be related to its reparative and/or neuroprotective effects.…”

Section: Discussionmentioning

confidence: 99%

Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

Schiavon

Bonato

Milani

et al. 2016

Progress in Neuro-Psychopharmacology and Biological Psychiatry

116

View full text Add to dashboard Cite

“…Collaterally, we evaluated the therapeutic profile of the 9 -THC and CBD combination in WT littermates used as a model of aging. We chose the combination of these two natural cannabinoids because, although previous findings revealed that both 9 -THC and CBD given alone resulted in beneficial cognitive effects in A␤PP/PS1 mice [13,16,17], the combination of 9 -THC and CBD was more effective than either cannabinoid alone in these transgenic animals when administered at early stages [13].…”

Section: Discussionmentioning

confidence: 99%

Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model

Aso

Andrés‐Benito

Ferrer

2016

JAD

View full text Add to dashboard Cite

Abstract. Previous reports have demonstrated that the combination of 9 -tetrahydrocannabinol ( 9 -THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimerlike phenotype of A␤PP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Here, we provide evidence that such natural cannabinoids are still effective in reducing memory impairment in A␤PP/PS1 mice at advanced stages of the disease but are not effective in modifying the A␤ processing or in reducing the glial reactivity associated with aberrant A␤ deposition as occurs when administered at early stages of the disease. The present study also demonstrates that natural cannabinoids do not affect cognitive impairment associated with healthy aging in wild-type mice. The positive effects induced by 9 -THC and CBD in aged A␤PP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Rα1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.

show abstract

Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice

Abstract: This is the first study to investigate the effect of chronic CBD treatment on cognition in an AD transgenic mouse model. Our findings suggest that CBD may have therapeutic potential for specific cognitive impairments associated with AD.

Cited by 144 publications

References 70 publications

Medical marijuana in neurology

Medical marijuana in neurology

Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model

Contact Info

Product

Resources

About